View in EDS PDF Full Text

Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.

Saved in:
Bibliographic Details
Title: Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.
Authors: Fond, G., Boyer, L., Favez, M., Brunel, L., Aouizerate, B., Berna, F., Capdevielle, D., Chereau, I., Dorey, J., Dubertret, C., Dubreucq, Faget, C., Gabayet, F., Laouamri, H., Lancon, C., Strat, Y., Misdrahi, D., Rey, R., Passerieux, C., Schandrin, A.
Source: Psychopharmacology. Feb2016, Vol. 233 Issue 4, p571-578. 8p.
Subjects: Aggression (Psychology), Schizophrenia treatment, Medication abuse, Second-generation antidepressants, Antipsychotic agents, Drug administration, Drug side effects
Abstract: Introduction: The primary objective of this study was to determine if second-generation antipsychotic (SGA) administration was associated with lower aggressiveness scores compared to first-generation (FGA) in schizophrenia (SZ). The secondary objective was to determine if antidepressants, mood stabilizers, and benzodiazepines administration were respectively associated with lower aggressiveness scores compared to patients who were not administered these medications. Methods: Three hundred thirty-one patients with schizophrenia ( N = 255) or schizoaffective disorder ( N = 76) (mean age = 32.5 years, 75.5 % male gender) were systematically included in the network of FondaMental Expert Center for Schizophrenia and assessed with the structured clinical interview for DSM-IV Axis I disorders and validated scales for psychotic symptomatology, insight, and compliance. Aggressiveness was measured by the Buss-Perry Aggression Questionnaire (BPAQ) score. Ongoing psychotropic treatment was recorded. Results: Patients who received SGA had lower BPAQ scores than patients who did not ( p = 0.01). More specifically, these patients had lower physical and verbal aggression scores. On the contrary, patients who received benzodiazepines had higher BPAQ scores than patients who did not ( p = 0.04). No significant difference was found between BPAQ scores of patients respectively being administered mood stabilizers (including valproate), antidepressant, and the patients who were not. These results were found independently of socio-demographical variables, psychotic symptomatology, insight, compliance into treatment, daily-administered antipsychotic dose, the way of antipsychotic administration (oral vs long acting), current alcohol disorder, and daily cannabis consumption. Conclusion: The results of the present study are in favor of the choice of SGA in SZ patients with aggressiveness, but these results need further investigation in longitudinal studies. Given the potent side effects of benzodiazepines (especially dependency and cognitive impairment) and the results of the present study, their long-term prescription is not recommended in patients with schizophrenia and aggressive behavior. [ABSTRACT FROM AUTHOR]
Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 112463452
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Fond%2C+G%2E%22">Fond, G.</searchLink><br /><searchLink fieldCode="AR" term="%22Boyer%2C+L%2E%22">Boyer, L.</searchLink><br /><searchLink fieldCode="AR" term="%22Favez%2C+M%2E%22">Favez, M.</searchLink><br /><searchLink fieldCode="AR" term="%22Brunel%2C+L%2E%22">Brunel, L.</searchLink><br /><searchLink fieldCode="AR" term="%22Aouizerate%2C+B%2E%22">Aouizerate, B.</searchLink><br /><searchLink fieldCode="AR" term="%22Berna%2C+F%2E%22">Berna, F.</searchLink><br /><searchLink fieldCode="AR" term="%22Capdevielle%2C+D%2E%22">Capdevielle, D.</searchLink><br /><searchLink fieldCode="AR" term="%22Chereau%2C+I%2E%22">Chereau, I.</searchLink><br /><searchLink fieldCode="AR" term="%22Dorey%2C+J%2E%22">Dorey, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Dubertret%2C+C%2E%22">Dubertret, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Dubreucq%22">Dubreucq</searchLink><br /><searchLink fieldCode="AR" term="%22Faget%2C+C%2E%22">Faget, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Gabayet%2C+F%2E%22">Gabayet, F.</searchLink><br /><searchLink fieldCode="AR" term="%22Laouamri%2C+H%2E%22">Laouamri, H.</searchLink><br /><searchLink fieldCode="AR" term="%22Lancon%2C+C%2E%22">Lancon, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Strat%2C+Y%2E%22">Strat, Y.</searchLink><br /><searchLink fieldCode="AR" term="%22Misdrahi%2C+D%2E%22">Misdrahi, D.</searchLink><br /><searchLink fieldCode="AR" term="%22Rey%2C+R%2E%22">Rey, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Passerieux%2C+C%2E%22">Passerieux, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Schandrin%2C+A%2E%22">Schandrin, A.</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Psychopharmacology%22">Psychopharmacology</searchLink>. Feb2016, Vol. 233 Issue 4, p571-578. 8p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Aggression+%28Psychology%29%22">Aggression (Psychology)</searchLink><br /><searchLink fieldCode="DE" term="%22Schizophrenia+treatment%22">Schizophrenia treatment</searchLink><br /><searchLink fieldCode="DE" term="%22Medication+abuse%22">Medication abuse</searchLink><br /><searchLink fieldCode="DE" term="%22Second-generation+antidepressants%22">Second-generation antidepressants</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+administration%22">Drug administration</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+side+effects%22">Drug side effects</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: The primary objective of this study was to determine if second-generation antipsychotic (SGA) administration was associated with lower aggressiveness scores compared to first-generation (FGA) in schizophrenia (SZ). The secondary objective was to determine if antidepressants, mood stabilizers, and benzodiazepines administration were respectively associated with lower aggressiveness scores compared to patients who were not administered these medications. Methods: Three hundred thirty-one patients with schizophrenia ( N = 255) or schizoaffective disorder ( N = 76) (mean age = 32.5 years, 75.5 % male gender) were systematically included in the network of FondaMental Expert Center for Schizophrenia and assessed with the structured clinical interview for DSM-IV Axis I disorders and validated scales for psychotic symptomatology, insight, and compliance. Aggressiveness was measured by the Buss-Perry Aggression Questionnaire (BPAQ) score. Ongoing psychotropic treatment was recorded. Results: Patients who received SGA had lower BPAQ scores than patients who did not ( p = 0.01). More specifically, these patients had lower physical and verbal aggression scores. On the contrary, patients who received benzodiazepines had higher BPAQ scores than patients who did not ( p = 0.04). No significant difference was found between BPAQ scores of patients respectively being administered mood stabilizers (including valproate), antidepressant, and the patients who were not. These results were found independently of socio-demographical variables, psychotic symptomatology, insight, compliance into treatment, daily-administered antipsychotic dose, the way of antipsychotic administration (oral vs long acting), current alcohol disorder, and daily cannabis consumption. Conclusion: The results of the present study are in favor of the choice of SGA in SZ patients with aggressiveness, but these results need further investigation in longitudinal studies. Given the potent side effects of benzodiazepines (especially dependency and cognitive impairment) and the results of the present study, their long-term prescription is not recommended in patients with schizophrenia and aggressive behavior. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=112463452
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00213-015-4167-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 8
        StartPage: 571
    Subjects:
      – SubjectFull: Aggression (Psychology)
        Type: general
      – SubjectFull: Schizophrenia treatment
        Type: general
      – SubjectFull: Medication abuse
        Type: general
      – SubjectFull: Second-generation antidepressants
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
      – SubjectFull: Drug administration
        Type: general
      – SubjectFull: Drug side effects
        Type: general
    Titles:
      – TitleFull: Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fond, G.
      – PersonEntity:
          Name:
            NameFull: Boyer, L.
      – PersonEntity:
          Name:
            NameFull: Favez, M.
      – PersonEntity:
          Name:
            NameFull: Brunel, L.
      – PersonEntity:
          Name:
            NameFull: Aouizerate, B.
      – PersonEntity:
          Name:
            NameFull: Berna, F.
      – PersonEntity:
          Name:
            NameFull: Capdevielle, D.
      – PersonEntity:
          Name:
            NameFull: Chereau, I.
      – PersonEntity:
          Name:
            NameFull: Dorey, J.
      – PersonEntity:
          Name:
            NameFull: Dubertret, C.
      – PersonEntity:
          Name:
            NameFull: Dubreucq
      – PersonEntity:
          Name:
            NameFull: Faget, C.
      – PersonEntity:
          Name:
            NameFull: Gabayet, F.
      – PersonEntity:
          Name:
            NameFull: Laouamri, H.
      – PersonEntity:
          Name:
            NameFull: Lancon, C.
      – PersonEntity:
          Name:
            NameFull: Strat, Y.
      – PersonEntity:
          Name:
            NameFull: Misdrahi, D.
      – PersonEntity:
          Name:
            NameFull: Rey, R.
      – PersonEntity:
          Name:
            NameFull: Passerieux, C.
      – PersonEntity:
          Name:
            NameFull: Schandrin, A.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 02
              Text: Feb2016
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-print
              Value: 00333158
          Numbering:
            – Type: volume
              Value: 233
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Psychopharmacology
              Type: main
ResultId 1